---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-006916"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T05:03:14.066397+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# VolitionRx appoints Timothy Still as Chairman, effective November 6, 2024

## Summary
- Timothy Still appointed non-executive Chairman and director of VolitionRx; board expanded to 8 members.
- Still has 35+ years in diagnostics, most recently President/CEO of Sense Biodetection (merged with Sherlock).
- Compensation includes $30K/quarter retainer, 400K time-vested RSUs, and 1M performance-based RSUs tied to $2.50/$5.00 stock price targets.
- Annual RSU grant of 300K shares contingent on corporate goals, subject to share availability under incentive plans.

## SEC filing metadata
- accession: 0001477932-24-006916
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793224006916/0001477932-24-006916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793224006916/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-006916
- JSON: https://secwatch.observer/filing/0001477932-24-006916.json
- Plain text: https://secwatch.observer/filing/0001477932-24-006916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.